Dennis John McCance, Queen's University, Belfast, Northern Ireland, UK
Published online: September 2009
DOI: 10.1002/9780470015902.a0000421.pub2
Infectious agents account for appropriately 25% of cancers worldwide and viruses in particular have been useful in elucidating many of the cellular pathways that can be deregulated in cancer. Therefore, the more that is known about how viral proteins disrupt the normal cell the more we will learn about important regulatory pathways that when altered or abrogated, lead to a transformed cell.
Keywords: DNA; RNA; transformation; immortalization; tumours
| References | |
| Brehm A, Miska EA, McCance DJ et al. (1998) Retinoblastoma recruits histone deacetylase activity to repress transcription. Nature 391: 597–601. | |
| Chang MH, Chen CJ, Lai MS et al. (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New England Journal of Medicine 336: 1855–1859. | |
| Chang Y, Cesarman E, Pessin MS et al. (1994) Identifiaction of herpes-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 265: 1865–1869. | |
| Gardiol D, Kühne C, Glaunsinger B et al. (1999) Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18: 5487–5496. | |
| Horikawa I and Barrett JC (2003) Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24: 1167–1176. | |
| Huibregtse J, Schneffner M and Howley PM (1991) A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 and 18. EMBO Journal 10: 4129–4135. | |
| Kwok RP, Laurance ME, Lunblad JR et al. (1996) Control of cAMP-regulated enchancers by the viral transactivator Tax through CREB and co-activator CBP. Nature 380: 642–646. | |
| Mosialos G, Birkenbach M, Yalamanchill R et al. (1995) The Epstein–Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80: 189–399. | |
| Ray RB, Steele R, Meyer K and Ray R (1997) Transcriptional repression of p53 promoter by hepatitis C virus core protein. Journal of Biological Chemistry 272: 10983–10986. | |
| Straight SW, Herman B and McCance DJ (1995) The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. Journal of Virology 69: 3185–3192. | |
| Swanton C, Mann DJ, Fleckstein B et al. (1997) Herpes-cyclin.cdk6 complexes evade inhibition by cdk inhibitor proteins. Nature 390: 184–187. | |
| Transy C, Fourel G, Robinson WS et al. (1992) Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with hepadnavirus. Proceedings of the National Academy of Sciences of the USA 89: 3874–3878. | |
| Wheeler CM (2007) Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Natural Clinical Practice 4: 224–235. | |
| Further Reading | |
| Brechot C (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 127: S56–S61. | |
| Ganem D (2006) KSHV infection and the pathogenesis of Kaposi's sarcoma. Annual Review of Pathology 1: 273–296. | |
| Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25: 3834–3847. | |
| book Saveria Campo M (ed.) (2006) Papillomavirus Research – From Natural History to Vaccines and Beyond. Norfolk, UK: Caister Academic Press. | |
| Thorley-Lawson DA and Allday MJ (2008) The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nature Reviews of Microbiology 6: 913–924. | |
Copyright © 2000-2013 by John Wiley & Sons, Inc., or related companies. All rights reserved.
